Fixed-Dose Combination Formulation and Development of Tamsulosin Hydrochloride and Dutasteride

Fixed-Dose Combination Formulation and Development of Tamsulosin Hydrochloride and Dutasteride

碩士 === 元培醫事科技大學 === 生物科技暨製藥技術系碩士班 === 104 === Abstract The objective of the study was to determine the optimum composition for controlled-release core pellets of tamsulosin hydrochloride (TSH) and immediate-release outer layer of Dutasteride (DTS) for orally multi-particulate pellets. An optimized f...

Full description

Bibliographic Details
Main Authors:	CHOU,MING-CHERNG, 周明誠
Other Authors:	LIN,HONG-LIANG
Format:	Others
Language:	zh-TW
Published:	2016
Online Access:	http://ndltd.ncl.edu.tw/handle/91900838247392203179

Similar Items

Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia
by: Konstantinos Dimitropoulos, et al.
Published: (2016-02-01)

A comparative study of fixed dose of Tamsulosin with finasteride vs Tamsulosin with dutasteride in the management of benign prostatic hyperplasia
by: N K Mohanty, et al.
Published: (2006-01-01)

Simultaneous estimation of dutasteride and tamsulosin hydrochloride in tablet dosage form by vierordt’s method
by: P. Giriraj, et al.
Published: (2017-05-01)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
by: Barkin J
Published: (2011-10-01)

Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
by: J Miller, et al.
Published: (2009-06-01)

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia
by: Bilal Chughtai, et al.
Published: (2012-10-01)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
by: Zhongbao Zhou, et al.
Published: (2019-03-01)

Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin
by: Gonzalo Villapalos-García, et al.
Published: (2021-10-01)

Formulation design of tamsulosin hydrochloride orally disintegrating sustained-release tablets
by: Ling-Lun Weng, et al.
Published: (2012)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
by: Djavan B, et al.
Published: (2011-03-01)

Development and formulation for Dutasteride hard capsules dosage form
by: LIU,MING-SIAN, et al.
Published: (2016)

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial
by: Andreas Bohle
Published: (2011-04-01)

SUCCESS RATES OF TAMSULOSIN AND DUTASTERIDE AS MEDICAL THERAPY BASED ON IPSS IN SYMPTOMATIC BPH PATIENTS IN ARIFIN ACHMAD HOSPITAL PEKANBARU RIAU
by: Zuhirman Zamzami
Published: (2018-07-01)

Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial
by: Shin YS, et al.
Published: (2016-09-01)

DETERMINATION OF TAMSULOSIN HYDROCHLORIDE RELEASE PHARMACOKINETICS IN PROSTATE GLAND BY A RADIOTRACER METHOD
by: V. I. Grytsenko, et al.
Published: (2013-10-01)

Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
by: Dimitropoulos K, et al.
Published: (2015-03-01)

The Effect of Combined Therapy with Tamsulosin Hydrochloride and Meloxicam in Patients with Benign Prostatic Hyperplasia Symptoms and Impact on Nocturia and Sleep Quality
by: Sacit Nuri Gorgel, et al.
Published: (2013-09-01)

A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement
by: Chenthil Perumal, et al.
Published: (2015-01-01)

Development and validation of an HPLC method for the simultaneous determination of artesunate and mefloquine hydrochloride in fixed-dose combination tablets
by: Fernando Henrique Andrade Nogueira, et al.
Published: (2013-12-01)

Preparation and evaluation of tamsulosin hydrochloride sustained-release pellets modified by two-layered membrane techniques
by: Jingmin Wang, et al.
Published: (2015-02-01)

Use of dutasteride in carcinoma prostate
by: R P Shrinivas
Published: (2014-01-01)

Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasteride
by: Baek I, et al.
Published: (2015-06-01)

Orally disintegrating tablets : formulation development, novel engineering solutions and fixed dose combinations
by: Dennison, Thomas
Published: (2017)

RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF FINASTERIDE AND TAMSULOSIN IN TABLET FORMULATIONS
by: Ashu Mittal, et al.
Published: (2015-01-01)

Formulation of carbamazepine and sodium valproate fixed dose combination for management of epilepsy
by: Seabi, Mmakgomo Eunice
Published: (2020)

Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy in LUTS/BPH patients with moderate-severe symptoms at risk of disease progression: Results from clinical trial simulations using risk of AUR or BPH-related surgery
by: J.M. Palacios Moreno, et al.
Published: (2020-07-01)

Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride
by: Hassan El-Tatawy, et al.
Published: (2015-09-01)

Preparation and stability investigation of tamsulosin hydrochloride sustained release pellets containing acrylic resin polymers with two different techniques
by: Rui Fan, et al.
Published: (2017-03-01)

‘Tamsulosin and Darifenacin’ Versus ‘Tamsulosin Monotherapy’ for ‘BPH with Accompanying Overactive Bladder’
by: IQBAL SINGH, et al.
Published: (2015-06-01)

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction
by: Sun Tae Ahn, et al.
Published: (2020-01-01)

Formulation, development and evaluation of lipid nanocarriers for minocycline hydrochloride
by: Ranchhod, Janeeta
Published: (2017)

Formulation development, manufacture and evaluation of hydralazine hydrochloride microspheres
by: Kangausaru, Shakemore Tinashe
Published: (2017)

THE EFFECTIVENESS OF TAMSULOSIN, SOLIFENACIN, AND COMBINATIONS THERAPY TAMSULOSIN ADDED SOLIFENACIN ON LOWER URINARY TRACT SYMPTOMS AFTER DOUBLE J STENT INSERTION
by: Ida Bagus Putra Pramana, et al.
Published: (2019-07-01)

Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets
by: Anteneh Belayneh, et al.
Published: (2020-01-01)

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe
by: Omar ePatiño-Rodríguez, et al.
Published: (2014-11-01)

Update on the use of dutasteride in the management of benign prostatic hypertrophy
by: Joe Miller, et al.
Published: (2007-04-01)

Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice.
by: Alexander B Opoku-Acheampong, et al.
Published: (2013-01-01)

Electrochemical Quantitative Assessment of Labetalol Hydrochloride in Pure Form and Combined Pharmaceutical Formulations
by: Maissa Yacoub Salem, et al.
Published: (2020-06-01)

Fixed and separate combination of solifenacin and tamsulosin in urinary disorders associated with benign prostatic hyperplasia: a choice based on price and value comparison
by: A. G. Tolkushin, et al.
Published: (2019-08-01)

Finasteride and Tamsulosin Combination in Benign Prostatic Enlargement in a Tertiary Hospital
by: Binod Bade Shrestha, et al.
Published: (2015-03-01)

Cannot write session to /tmp/vufind_sessions/sess_326immfcaj8eks8saiplqefqc0